A recent study indicates that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional lifestyle programs.
Findings released in a leading medical journal points out that while obese people frequently drop about a fifth of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing such drugs must be informed of the potential of quick weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment weight within about one and a half years.
Comparing Treatments
The study, which looked at dozens of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with other pills.
Scientists note that people who shed pounds through diet and exercise typically have a slower creep back—around 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Doctors suggest the way of the injections is key to understanding the amplified weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 levels far above than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication means hunger is no longer kept in check, making excessive eating much more probable."
An Ongoing Disease?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, due to the significant potential of relapse, the treatment might need to be long-term.
This perspective is supported by pharmaceutical companies, who state that the results "emphasize the long-term character of excess weight," similar to managing diseases like hypertension.
Patient Accounts
People who have come off the medication explain a sudden resurgence of appetite.
"It felt as if a trigger activating and I was suddenly ravenous," described an individual.
The struggle is compounded if patients have not adopted permanent lifestyle or habit modifications during therapy.
Growing Interest
Recent estimates suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is higher among females compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Finally, clinicians stress that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent solution and lasting health benefits relies on integrated behavioural support.
